NATIONAL
CANCER
INSTITUTE

NCI Cancer Bulletin
A Trusted Source for Cancer Research News
November 18, 2008 • Volume 5 / Number 23 E-Mail This Document  |  Download PDF  |  Bulletin Archive/Search  |  Subscribe


Bulletin Home

Featured Article
NCI Technology Research Facility Gets Off the Ground

Cancer Research Highlights
Bevacizumab May Increase Blood Clot Risk

Number of Adult U.S. Smokers Drops, But So Do Quit Attempts

PAX2 Protein Mediates Effect of Tamoxifen in Breast Cancer

Burden of Cervical Cancer Prior to HPV Vaccine Assessed

Director's Update
Building an Advanced Technology Research Initiative

FDA Update
New Option Approved for Indolent NHL

Special Report
A Cancer Genome is Sequenced, Revealing Rare Mutations

Featured Clinical Trial
New Drug for Patients with Advanced Thyroid Cancer

Special Issue on Cancer Imaging

Spotlight
Cancer Disparities: A Biological and Psychosocial Perspective

Also in the Journals

Community Update
Researchers Consider "NCI Translates" Approach

Notes
NCI Advisors Approve Major Cancer Research Initiatives

Understanding NCI Teleconference: Translational Research Working Group

In Memoriam
Dr. Ronald M. Davis

Cancer Center Profile
Memorial Sloan-Kettering Cancer Center

Bulletin Archive

About the Bulletin

Page Options
Print This Page
Print This Document
View Entire Document
E-Mail This Document
View/Print PDF
Notes

NCI Advisors Approve Major Cancer Research Initiatives
Earlier this month NCI's Board of Scientific Advisors (BSA) reviewed and endorsed several of the institute's major, cutting-edge scientific endeavors. Board members approved a proposal that provides 5-year funding for a new network of 4 to 6 physical sciences oncology centers. These centers, which were conceptualized during a series of "think tank" meetings NCI convened this year, would formally engage scientific teams from the fields of physics, mathematics, chemistry, and engineering, to examine cancer using new and often nontraditional approaches.

The BSA also recommended a 5-year renewal of The Cancer Genome Atlas, NCI's joint pilot project with the National Human Genome Research Institute. The pilot has already provided valuable insights into the biology of and potential new treatment approaches for brain cancer. NCI's Division of Cancer Biology's Integrative Cancer Biology Program also received strong support from the BSA, which recommended a 5-year renewal of that program.

Understanding NCI Teleconference: Translational Research Working Group
NCI's Office of Advocacy Relations' next "Understanding NCI" teleconference, titled "Transforming Translation: Implementation of the Translational Research Working Group (TRWG) Report," will take place December 16 from 1:00–2:00 p.m., ET. The featured speakers will be Dr. Lynn Matrisian, TRWG Co-Chair and special assistant to the NCI Director, and Ms. Gwen Darien, editor-in-chief of CR magazine and director of the Survivor and Patient Advocacy Program at the American Association for Cancer Research. A question-and-answer session for participants will follow the presentations.

No registration is required for participation. To join the teleconference, dial 1-800-857-6584; the passcode is: TRWG. Toll-free playback will be available through January 16, 2009 at 1-866-431-2907. A recording of the previous teleconference on P.L.A.N.E.T.: 5-Step Guide to Cancer Control Planning and Programming is available through December 12 at 1-866-434-5243.

< Previous Section  |  Next Section >


A Service of the National Cancer Institute
Department of Health and Human Services National Institutes of Health USA.gov